Sarepta slumps 9% on golodirsen trial trouble
News that US RNA-based drug developer Sarepta Therapeutics (Nasdaq: SRPT) had been forced to halt a UK trial in Duchenne muscular dystrophy sent the company’s share price tumbling by 9% to $51.94 in three hours of trading on Friday.
News analysis service EP Vantage broke the news on Friday – confirmed by the company - that the UK element of the ESSENCE trial of golodirsen had been temporarily stopped due to a serious adverse event, having learnt of the issue when a parent wrote about it in a Facebook post.
The article adds that the parent posted that she understood rhabdomyolysis side effects to be the reason for the action taken, which has only affected the research being conducted in the UK. Patients are also taking part in the USA, Israel and eight European countries.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze